Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT) have been given a consensus recommendation of “Moderate Buy” by the eleven ratings firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $26.25.

SGMT has been the subject of several research analyst reports. Barclays initiated coverage on shares of Sagimet Biosciences in a research note on Tuesday, January 27th. They issued an “equal weight” rating and a $8.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $29.00 price objective on shares of Sagimet Biosciences in a research note on Wednesday, March 11th. Guggenheim initiated coverage on shares of Sagimet Biosciences in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $27.00 price objective for the company. Wall Street Zen upgraded shares of Sagimet Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Sagimet Biosciences in a research note on Tuesday, April 21st.

Insider Buying and Selling at Sagimet Biosciences

In other news, CEO David Happel sold 12,101 shares of the stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $5.36, for a total transaction of $64,861.36. Following the completion of the sale, the chief executive officer owned 677,621 shares in the company, valued at approximately $3,632,048.56. This represents a 1.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 14.70% of the company’s stock.

Institutional Investors Weigh In On Sagimet Biosciences

Several hedge funds have recently made changes to their positions in SGMT. Affinity Asset Advisors LLC boosted its stake in shares of Sagimet Biosciences by 228.1% during the fourth quarter. Affinity Asset Advisors LLC now owns 1,148,245 shares of the company’s stock worth $6,798,000 after buying an additional 798,245 shares during the period. Millennium Management LLC boosted its stake in shares of Sagimet Biosciences by 6,484.7% during the third quarter. Millennium Management LLC now owns 776,377 shares of the company’s stock worth $5,326,000 after buying an additional 788,537 shares during the period. Marshall Wace LLP acquired a new stake in shares of Sagimet Biosciences during the fourth quarter worth about $4,620,000. Schonfeld Strategic Advisors LLC boosted its stake in shares of Sagimet Biosciences by 462.4% during the third quarter. Schonfeld Strategic Advisors LLC now owns 523,774 shares of the company’s stock worth $3,593,000 after buying an additional 430,644 shares during the period. Finally, Hudson Bay Capital Management LP acquired a new stake in shares of Sagimet Biosciences during the fourth quarter worth about $1,802,000. Institutional investors and hedge funds own 87.86% of the company’s stock.

Sagimet Biosciences Price Performance

NASDAQ:SGMT opened at $5.86 on Monday. Sagimet Biosciences has a 12 month low of $3.00 and a 12 month high of $11.41. The firm has a market capitalization of $190.92 million, a PE ratio of -3.73 and a beta of 3.17. The business’s fifty day moving average price is $5.43 and its 200 day moving average price is $6.26.

Sagimet Biosciences (NASDAQ:SGMT) last released its quarterly earnings data on Wednesday, March 11th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.14. As a group, equities analysts anticipate that Sagimet Biosciences will post -1.75 EPS for the current year.

Sagimet Biosciences Company Profile

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.